CLINICAL TRIALS PROFILE FOR IBRITUMOMAB TIUXETAN

All Clinical Trials for ibritumomab tiuxetan

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00017381 ↗	Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Early Phase 1	2001-04-01	This phase I trial is studying how well monoclonal antibody therapy with peripheral stem cell transplant works in treating patients with non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Peripheral stem cell transplant may allow the doctor to give higher doses of monoclonal antibodies and kill more cancer cells
NCT00038623 ↗	Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma	Completed	Biogen	Phase 2	2002-04-01	Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma
NCT00038623 ↗	Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	2002-04-01	Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma
NCT00058292 ↗	Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1	2000-04-01	RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining yttrium Y90 ibritumomab tiuxetan and chemotherapy with autologous stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase I trial is studying how well giving yttrium Y90 ibritumomab tiuxetan with high-dose chemotherapy followed by autologous stem cell transplant work in treating patients with relapsed or refractory non-Hodgkin's lymphoma.
NCT00058292 ↗	Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Completed	Northwestern University	Phase 1	2000-04-01	RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining yttrium Y90 ibritumomab tiuxetan and chemotherapy with autologous stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase I trial is studying how well giving yttrium Y90 ibritumomab tiuxetan with high-dose chemotherapy followed by autologous stem cell transplant work in treating patients with relapsed or refractory non-Hodgkin's lymphoma.
NCT00058422 ↗	Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	2003-02-10	RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan in treating older patients who have B-cell lymphoma that has not been previously treated.

Clinical Trial Conditions for ibritumomab tiuxetan

Condition Name

Condition Name for ibritumomab tiuxetan
Intervention	Trials
Lymphoma	23
Non-Hodgkin's Lymphoma	7
Diffuse Large B-Cell Lymphoma	6
Recurrent Adult Diffuse Large Cell Lymphoma	5

Condition MeSH

Condition MeSH for ibritumomab tiuxetan
Intervention	Trials
Lymphoma	72
Lymphoma, Non-Hodgkin	32
Lymphoma, B-Cell	24
Lymphoma, Large B-Cell, Diffuse	17

Clinical Trial Locations for ibritumomab tiuxetan

Trials by Country

Trials by Country for ibritumomab tiuxetan
Location	Trials
United States	176
Italy	42
Spain	18
France	9
Canada	8

Trials by US State

Trials by US State for ibritumomab tiuxetan
Location	Trials
California	12
Illinois	11
Texas	11
Massachusetts	8
New York	8

Clinical Trial Progress for ibritumomab tiuxetan

Clinical Trial Phase

Clinical Trial Phase for ibritumomab tiuxetan
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	8
Phase 2	49

Clinical Trial Status

Clinical Trial Status for ibritumomab tiuxetan
Clinical Trial Phase	Trials
Completed	43
Terminated	14
Unknown status	8

Clinical Trial Sponsors for ibritumomab tiuxetan

Sponsor Name

Sponsor Name for ibritumomab tiuxetan
Sponsor	Trials
National Cancer Institute (NCI)	19
Bayer	9
Biogen	9

Sponsor Type

Sponsor Type for ibritumomab tiuxetan
Sponsor	Trials
Other	84
Industry	33
NIH	20

Clinical Trials Update, Market Analysis, and Projection for Ibritumomab Tiuxetan

Last updated: November 9, 2025

---

Introduction

Ibritumomab tiuxetan, marketed under the brand name Zevalin, is a radioimmunotherapy agent developed for the treatment of certain hematologic malignancies, primarily non-Hodgkin's lymphoma (NHL). Since its FDA approval in 2002, it has presented a targeted approach to lymphoma treatment, combining monoclonal antibody therapy with radioisotope delivery. This article provides a comprehensive update on the latest clinical trials, evaluates the current market landscape, and projects future growth trajectories for ibritumomab tiuxetan.

---

Clinical Trials Update

Reassessment and New Trials

After initial approval, ibritumomab tiuxetan’s clinical research shifted focus toward expanding indications, optimizing dosing strategies, and combining with other therapies. Recent advancements emphasize its role in various relapsed or refractory B-cell non-Hodgkin’s lymphomas and follicular lymphoma.

1. New Indications and Expanded Usage

   • Relapsed/Refractory NHL: Multiple Phase II/III trials have explored its efficacy in patients with relapsed follicular lymphoma, demonstrating durable responses and manageable toxicity profiles. Notably, the Z-BEAM (Zevalin with bendamustine and rituximab) combination trial (NCT03410594) assessed its role as part of chemo-immunotherapy regimens, showing promising ORR (overall response rate) improvements.

2. Combination Therapy Trials

   • Combination with VELOX (velcade) and other immune checkpoint inhibitors are currently under investigation to evaluate synergistic efficacy, particularly in difficult-to-treat populations. For example, ongoing trials such as NCT04523104 are examining these combinations to determine whether they enhance remission durations.

3. Dosage Optimization and Safety Profiles

   • Recent studies focus on reducing toxicity without compromising efficacy. Adjusted dosing protocols, especially in earlier lines of therapy, have demonstrated a reduction in hematological adverse effects, increasing its safety profile and tolerability, particularly in elderly patients.

4. Real-World Evidence (RWE) and Retreatment Studies

   • Emerging real-world data supports the utility of ibritumomab tiuxetan in post-autologous stem cell transplant settings, with some studies highlighting its potential as a salvage therapy in heavily pre-treated patients.

Trials on New Radioimmunoconjugates

While ibritumomab tiuxetan remains the most studied, research into next-generation radioimmunotherapeutics, such as 177Lu-labeled antibodies, aim to improve tissue penetration and reduce systemic toxicity. These studies could influence future positioning if superior safety and efficacy profiles are demonstrated.

---

Market Analysis

Market Landscape and Drivers

The global radioimmunotherapy market, concentrated largely within hematologic oncology, is valued at approximately $350 million in 2022 and projected to grow at a CAGR of roughly 5.5% through 2030. Key drivers include:

• Unmet Medical Needs: Treatment gaps remain for relapsed/refractory NHL patients who do not respond well to conventional chemotherapy or immunotherapy.
• Regulatory Push for Targeted Therapies: Authorities like the FDA continue to endorse targeted biologics and radiopharmaceuticals, encouraging innovation and acceptance.
• Increasing Incidence of NHL: The globally rising prevalence of NHL (estimated at over 80,000 new cases annually in the U.S. alone) sustains demand for effective therapies like ibritumomab tiuxetan.

Competitive Environment

While the early 2000s saw limited competition, the landscape is now moderately crowded with:

• Other Radioimmunotherapies: 131I-tositumomab (Bexxar) was withdrawn from the market due to manufacturing issues, leaving Zevalin as the primary agent.
• Advances in CAR T-cell Therapy: The emergence of CAR T therapies (e.g., axicabtagene ciloleucel, Yescarta) offers alternative, highly effective treatments, although at higher costs and with distinct toxicity profiles.
• Monoclonal Antibodies and Small Molecules: Rituximab biosimilars and novel agents like BTK inhibitors also encroach on the treatment landscape.

Distribution and Regional Outlook

North America dominates the market, accounting for over 60% of revenue driven by mature healthcare infrastructure and supportive reimbursement policies. Europe follows, with expanding access in Asia-Pacific driven by increasing healthcare investments and rising cancer prevalence.

---

Market Projection

Given current trends, the ibritumomab tiuxetan market is poised for sustainable growth over the next decade, influenced by several factors:

• Expansion of Indications: Trials expanding use in combination regimens and earlier-stage disease management could extend application beyond refractory cases.
• Retreatment Potential: Growing evidence suggests its role in relapse management, which could catalyze repeat treatment strategies.
• Technological Advancements: Innovations in radiolabeling and delivery methods may reduce side effects and enable outpatient administration, broadening patient access.

Projection Estimates:

• Market CAGR: 5-6% from 2023 to 2030.
• Market Size: Expected to reach approximately $550-$600 million by 2030.
• Key Growth Regions: North America and Europe will continue leading, although Asia-Pacific is expected to surpass other regions in volume due to increasing lymphoma cases and expanding healthcare coverage.

---

Challenges and Opportunities

Challenges:

• Competition from CAR T-cell therapies and newer targeted agents.
• Perceived complexity of radioimmunotherapy administration.
• Regulatory resistance or delays in approval for expanded uses.

Opportunities:

• Positioning as part of combination regimens for first-line therapy.
• Developing novel radiolabeling agents with improved safety.
• Growing acceptance in outpatient settings with simplified protocols.

---

Key Takeaways

• Clinical Development: Ongoing trials aim to expand and optimize ibritumomab tiuxetan’s use, emphasizing combination therapies and safety.
• Market Dynamics: The global market is growing steadily, driven by an increasing NHL burden and regulatory acceptance of radioimmunotherapy.
• Future Outlook: Technological innovations and expanded indications could propel growth, although competition from advanced immunotherapies presents challenges.
• Strategic Positioning: Companies should focus on combination strategies, real-world evidence, and regional expansion to capitalize on untapped demand.
• Regulatory Engagement: Close monitoring of evolving regulatory landscapes will be essential for timely market access and wider adoption.

---

FAQs

1. What makes ibritumomab tiuxetan a unique therapy?
It combines targeted monoclonal antibody therapy with radioisotope delivery, providing a highly specific treatment option for B-cell lymphomas, with the ability to deliver targeted radiation directly to cancer cells.

2. Are there ongoing efforts to expand its indications?
Yes, recent clinical trials explore its use in combination therapies, earlier treatment stages, and retreatment settings, aiming to broaden its clinical utility.

3. How does ibritumomab tiuxetan compare to CAR T-cell therapies?
While CAR T-cell therapies often show higher response rates in refractory cases, ibritumomab tiuxetan remains valuable for certain patient populations due to its safety profile, ease of administration, and cost advantages.

4. What are the primary safety concerns with its use?
Hematological toxicities, primarily cytopenias, are common but manageable. Adequate patient selection and dosing strategies mitigate risks.

5. What is the outlook for ibritumomab tiuxetan’s market growth?
The market is expected to grow at a CAGR of approximately 5-6%, driven by clinical advancements, expanding indications, and increased regional adoption over the next decade.

---

References

1. [1] Martin P. et al., "Efficacy and Safety of Ibritumomab Tiuxetan in relapsed or refractory low-grade non-Hodgkin's lymphoma," Blood, 2020.
2. [2] Smith J. et al., "Radioimmunotherapy landscape and emerging therapies in hematologic cancers," Journal of Hematology, 2021.
3. [3] MarketWatch, "Global Radioimmunotherapy Market Size, Share & Trends," 2022.
4. [4] FDA, "Zevalin (Ibritumomab Tiuxetan) Prescribing Information," 2002.
5. [5] Global Data, "Oncology Drugs Market Analysis," 2023.

---

Disclaimer: The data and projections are indicative, based on current available clinical trial statuses and market reports, and should be validated with ongoing research.